Mednax Inc. (NYSE:MD)’s share price fell 2.6% during mid-day trading on Thursday . The stock traded as low as $63.74 and last traded at $64.09, with a volume of 237,056 shares changing hands. The stock had previously closed at $65.77.

Several brokerages have recently issued reports on MD. Robert W. Baird reaffirmed a “buy” rating on shares of Mednax in a research note on Monday, May 16th. Zacks Investment Research raised Mednax from a “hold” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Wednesday, June 29th. Jefferies Group reissued a “buy” rating and issued a $80.00 target price on shares of Mednax in a research note on Wednesday, June 8th. JPMorgan Chase & Co. cut their target price on Mednax from $85.00 to $80.00 and set an “overweight” rating on the stock in a research note on Friday, July 29th. Finally, Citigroup Inc. cut their target price on Mednax from $76.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 17th. Four analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Mednax has a consensus rating of “Buy” and a consensus price target of $76.11.

The firm has a market cap of $6.14 billion and a P/E ratio of 18.58. The company has a 50 day moving average price of $68.19 and a 200-day moving average price of $68.22.

Mednax (NYSE:MD) last issued its quarterly earnings results on Thursday, July 28th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.07 by $0.04. The firm earned $772 million during the quarter, compared to the consensus estimate of $775.68 million. During the same quarter last year, the firm posted $0.90 EPS. The business’s revenue was up 14.1% on a year-over-year basis. On average, equities research analysts forecast that Mednax Inc. will post $4.14 EPS for the current year.

In related news, SVP Dominic J. Andreano sold 3,922 shares of the business’s stock in a transaction on Monday, June 13th. The stock was sold at an average price of $68.80, for a total transaction of $269,833.60. Following the sale, the senior vice president now owns 24,746 shares in the company, valued at approximately $1,702,524.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Karl B. Wagner sold 27,482 shares of the business’s stock in a transaction on Tuesday, June 7th. The stock was sold at an average price of $68.45, for a total value of $1,881,142.90. Following the sale, the insider now owns 105,932 shares in the company, valued at approximately $7,251,045.40. The disclosure for this sale can be found here.

A hedge fund recently raised its stake in Mednax stock. I.G. Investment Management LTD. increased its position in shares of Mednax Inc. (NYSE:MD) by 5.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,823 shares of the company’s stock after buying an additional 1,743 shares during the period. I.G. Investment Management LTD.’s holdings in Mednax were worth $2,280,000 at the end of the most recent quarter.

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.